According to Xconomy’s National Biotech Editor Luke Timmerman, the 24 biotech initial public offerings (IPOs) in 2013 are double those normally seen in an entire year since the financial crisis made investors more cautious about biotech investments. He reports that five more IPOs were expected as July came to a close. Timmerman, however, does not believe that “this IPO party” will last much longer. He cautions, “There are only so many good private companies worthy of graduating to the public markets. If the past is any indication (remember the genomics craze of 2000?), there will be a hangover when it ends.” See Xconomy.com, July 22, 2013.